MedTrace Logo

A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer

NCT01194609 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2014-05-09

No results posted yet for this study

Summary

Among the immune cell therapy, autologous adoptive immune cell therapy is a method to transfer the immune cells derived from peripheral white blood cells and expanded and stimulated with various cytokines and tumor specific antigens in cancer patients. Recently, the low-dose radiation is known to increase the immune response in many human cancer patients. In a clinical trial, 70% response rate with combination of low-dose radiation and adoptive immune cell therapy was reported in recurrent melanoma patients. This study is to investigate the feasibility of combination of low-dose radiation and autologous immune cell therapy in recurrent cervical cancer which is resistant to conventional palliative treatment.

Conditions

  • Uterine Cervical Neoplasms

Interventions

BIOLOGICAL

Immune cell

InnoLak two consecutive weeks every 3 weeks for 3 times

RADIATION

Low dose radiation

20cGy whole body radiation every three weeks for three times

Sponsors & Collaborators

  • Korea Cancer Center Hospital

    lead OTHER

Principal Investigators

  • Sang-Young Ryu, MD · Korea Institute of Radiological & Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-09-30
Completion
2012-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194609 on ClinicalTrials.gov